Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737697 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
A Phase 3 study, sponsored by ZS Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 754
- Enrollment target
NCT01737697: Completed Phase 3 study, sponsored by ZS Pharma.
NCT01737697 is a Phase 3 study that has completed, run by ZS Pharma. The registered enrollment target is 754 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737697, a Phase 3 study, has completed, sponsored by ZS Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 754 participants
- Enrollment target
Study Summary
Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 - 6.5 mmol/l versus no difference between ZS and placebo control (null hypothesis). Subacute Phase (randomized withdrawal): It is hypothesized that ZS once daily is more effective than placebo control (alternative hypotheses) in maintaining normokalemic levels (3.5 - 4.9 mmol/l) among subjects completing the Acute Phase versus no difference between each ZS dose and respective placebo controls (null hypotheses).
Interventions
- DRUG Zirconium silicate (acute phase)
- DRUG Zirconium silicate (subacute phase)
- DRUG Placebo (acute phase)
- DRUG Placebo ( subacute phase)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2012-11-30 |
| Est. Completion | 2013-11-30 |
| Phase | Phase 3 |
What the finished NCT01737697 record still lists
NCT01737697 is an interventional study that assigns participants to a tested intervention. The registered 754 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Zirconium silicate (acute phase) is the first listed.
NCT01737697 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01737697 about?
NCT01737697 is a clinical study titled "Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia". Acute Phase: It is hypothesized that ZS (zirconium silicate) is more effective than placebo control (alternative hypothesis) in lowering S-K levels in subjects with S-K between 5.0 - 6.5 mmol/l versus no difference between ZS and placebo control (null hypothesis). Subacute Phase (randomized withdra...
What is the current status of trial NCT01737697?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 754 participants. The study started on 2012-11-30. Estimated completion is 2013-11-30.
What interventions are being tested in trial NCT01737697?
The interventions under investigation include: Zirconium silicate (acute phase) (DRUG), Zirconium silicate (subacute phase) (DRUG), Placebo (acute phase) (DRUG), Placebo ( subacute phase) (DRUG).
Who is sponsoring clinical trial NCT01737697?
This trial is sponsored by ZS Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01737697's enrollment target sits among peer trials
754 460th of 2000 higher than 1,541 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI